ARTICLE | Finance
Neuron23’s pair of clinical programs move ahead with $96.5M series D: Venture Report
Plus: VCs back a Lexeo spinout, and more
June 26, 2025 11:57 PM UTC
The week’s largest venture round, a $96.5 million series D, went to Neuron23 as the biotech began a Phase II study of its lead program for Parkinson’s disease.
South San Francisco-based Neuron23 Inc. announced the funding along with news that it had dosed the first patient in the Phase II NEULARK trial of brain-penetrant LRRK2 inhibitor NEU-411. ...